Indeed, experimental combination drugs that pair GLP-1 agonists with compounds that raise levels of glucagon have recently ...

Pfizer has terminated the development of its oral obesity candidate danuglipron after a patient on a clinical trial with the ...

In one study, once-daily danuglipron resulted in one patient who experienced drug-related elevated liver enzymes.

Doer Biologics begins patient dosing in phase 2 study of DR10624 to treat metabolic dysfunction-associated steatotic liver disease and MASH: Hangzhou, China Thursday, April 24, 20 ...